Analisis Kejadian Interaksi Obat pada Pasien Skizofrenia di RSUD Dr. Iskak Tulungagung
DOI:
https://doi.org/10.59680/medika.v2i1.922Keywords:
Drugs, Interactions, SchizophreniaAbstract
Schizophrenia is a syndrome with multiple ethology, outcome differ depending on the chronic course of the diseases, and the balance of physical, genetic also influences in the country. Schizophrenia patients have psychotic symptoms, so the main psychopharmacology given to schizophrenia patients is antipsychotics. The main treatment for schizophrenia is antipsychotic drugs, many schizophrenia patients receive combination therapy with antipsychotic drugs. Drug interactions generally refer to changes in drug response resulting from a patient's exposure to a drug or other substance. The potential severity of interactions is important for evaluating the risks and benefits of alternative treatments. Severity is classified into mild severity (effects are usually mild), moderate severity (new effects may cause severity of the patient's disease), and severe severity (possibly life-threatening or may cause permanent damage). This study aims to determine drug interactions and treatment patterns regarding pharmacokinetic and pharmacodynamics interactions in schizophrenia patients at Iskak Tulungagung Hospital. The research method uses analytics with retrospective data collection. The research sample consisted of 48 respondents in the categories mild (2%), moderate (78%), and severe (20%). The results display is potential for drug interactions in the form of pharmacodynamics potential (97%) which dominates more than pharmacokinetic potential (3%).
References
Dipiro J, Talbert RL, Yee GC, Matzke GR, Wells BG, & Posey LM. (2015). Pharmacoterapy A Phatophysiologic Approach. In AIAA Guidance, Navigation, and Control Conference.
Baxter K. (2008). Stockley’s Drug Interactions. Annals of Pharmacotherapy, 40(6), 1219–1219. https://doi.org/10.1345/aph.1g691
Dipiro J, Talbert RL, Yee GC, Matzke GR, Wells BG, & Posey LM. (2015). Pharmacoterapy A Phatophysiologic Approach. In AIAA Guidance, Navigation, and Control Conference.
Kementerian Kesehatan RI. (2019). Situasi Kesehatan Jiwa di Indonesia. In Infodatin. https://pusdatin.kemkes.go.id/resources/download/pusdatin/infodatin/InfoDatin-Kesehatan-Jiwa.pdf.
Manggalawati, P. (2016). Potensi Interaksi Obat Antipsikotik Pada Pasien Skizofrenia Dewasa di Instalasi Rawat Inap Rumah Sakit Jiwa Daerah “X” periode Oktober – Desember tahun 2015. Skripsi.
Masturoh, Imas & Anggita T, N. (2018). Metodologi Penelitian Kesehatan. Kementrian Kesehatan Republik Indonesia
Parulian, L., 1, Listyanti2, E., & , Anita Kumala Hati1, I. S. (2019). Analisis Hubungan Polifarmasi Dan Interaksi Obat Pada Pasien Rawat Jalan Yang Mendapat Obat Hipertensi Di Rsp. Dr. Ario Wirawan Periode Januari-Maret 2019. 02(August), 79–86.
Putri, A. N., Susanto, Y., & Intannia, D. (2017). Interaksi Obat Terhadap Peresepan Antipsikotik Pasien Skizofrenia Dirumah Sakitjiwa Sambangl ihum Kalimantanselatan tahun 2011. Educational Psychology Journal, 2(2), 65–72. https://doi.org/DOI:
Ramdini, D. A., Sumiwi, S. A., Barliana, M. I., Destiani, D. P., & Nur, I. L. (2018). Potensi Interaksi Obat pada Pasien Skizofrenia di Salah Satu Rumah Sakit Jiwa di Provinsi Jawa Barat. Indonesian Journal of Clinical Pharmacy, 7(4), 280. https://doi.org/10.15416/ijcp.2018.7.4.280 The ICD-10 Classification of Mental and Behavioural Disorders. (n.d.). 1–267.
Zahnia, S., Sumekar, D. W., Kedokteran, F., Lampung, U., Ilmu, B., Komunitas, K., Masyarakat, K., & Kedokteran, F. (2013). Kajian Epidemiologis Skizofrenia Epidemiologic Study of Schizophrenia.
